Genmab and BioNTech to take BAbs all the way in crowded immuno-oncology
This article was originally published in Scrip
Executive Summary
Two European science-driven companies that retain ambitions to grow into independent sales-based pharmaceutical firms are to collaborate in immuno-oncology. Genmab and BioNTech (which also recently announced a separate deal with Eli Lilly) announced on 19 May that they would jointly research, develop and commercialize bispecific antibody (BAb) products. Both firms told Scrip that they had each the will and resources to commercialize any resultant products without licensing out to larger pharmaceutical third-parties.
You may also be interested in...
Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines
Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.